Alterations in immune responsiveness in women exposed to diethylstilbestrol in utero

Ways, Susan C.; Mortola, Joseph F.; Zvaifler, Nathan J.; Weiss, Regis J.; Yen, S. S. C.

doi:10.1016/s0015-0282(16)59341-8

Cited by 55 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suppression of immune response in transplantation patients who receive long-term immunosuppression therapy has been associated with a higher risk of melanoma [17]. Some studies suggested that DES daughters might be at higher risk of developing autoimmune diseases [18] or have an enhanced immune response to different mitogens [19, 20]. However, the relevance of autoimmune diseases to melanoma risk is unclear and an enhanced immune response would probably not be associated with an increased risk of melanoma.…”

Section: Discussionmentioning

confidence: 99%

Cancer risk in DES daughters

Verloop

Leeuwen

Helmerhorst

et al. 2010

Cancer Causes Control

View full text Add to dashboard Cite

ObjectiveWe examined long-term risk of cancer in women exposed to diethylstilbestrol (DES) in utero.MethodsA total of 12,091 DES-exposed women in the Netherlands were followed prospectively from December 1992 till June 2008. Cancer incidence was assessed through linkage with the Dutch pathology database (PALGA) and the Netherlands Cancer Registry and compared with the Dutch female population.ResultsA total of 348 medically verified cancers occurred; median age at end of follow-up was 44.0 years. No overall increased risk of cancer was found (standardized incidence ratio [SIR] = 1.01; 95% confidence interval [CI] = 0.91, 1.13). The risk of clear cell adenocarcinoma of the vagina and cervix (CCA) was statistically significantly increased (SIR = 24.23; 95% CI = 8.89, 52.74); the elevated risk persisted above 40 years of age. The risk of melanoma diagnosed before age 40 was increased (SIR = 1.59; 95% CI = 1.08, 2.26). No excess risks were found for other sites, including breast cancer.ConclusionsExcept for an elevated risk of CCA, persisting at older ages, and an increased risk of melanoma at young ages, we found no increased risk of cancer. Longer follow-up is warranted to examine cancer risk at ages when cancer occurs more frequently.Electronic supplementary materialThe online version of this article (doi:10.1007/s10552-010-9526-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer risk in DES daughters

Verloop

Leeuwen

Helmerhorst

et al. 2010

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Immunotoxicology in Drug Development

2010

Drug Safety Evaluation

View full text Add to dashboard Cite

Immunotoxicology in Drug Development

2010

Pharmaceutical Sciences Encyclopedia

View full text Add to dashboard Cite

Immunotoxicity evaluation of drugs has undergone fundamental changes following implementation of International Conference on Harmonisation (ICH) S8 guidelines. According to this current guideline, initial immunotoxicity assessment should be based on the evaluation of data already available from standard toxicity studies and other characteristics of the drug substance. This article aims to provide an understanding of adverse immunological effects, the types of preclinical tests that may be used to detect drugs, and approaches for testing and interpreting test results.

show abstract

Alterations in immune responsiveness in women exposed to diethylstilbestrol in utero

Cited by 55 publications

References 15 publications

Cancer risk in DES daughters

Cancer risk in DES daughters

Immunotoxicology in Drug Development

Immunotoxicology in Drug Development

Contact Info

Product

Resources

About